Our survival analyses clearly demonstrate that high HDAC2 expression is associated with shortened patient relapse-free survival time in prostate cancer, which is especially prominent in the clinically important and prognostically heterogeneous subgroup of patients with Gleason 7 carcinomas. Here, HDAC2 is linked to prostate carcinoma.